文献速递乳腺癌

贝伐珠单抗联合内分泌治疗用于HR阳性转移性乳腺癌一线治疗的汇总分析

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
PubMed 文献 · Eur J Cancer · 2019-07-02

该汇总分析纳入LEA和CALGB 40503两项III期随机试验的749例HR阳性转移性乳腺癌患者,比较内分泌治疗联合或不联合贝伐珠单抗的疗效。联合贝伐珠单抗显著延长无进展生存期(14.3 vs 19个月,HR 0.77),提高客观缓解率和临床获益率,但未改善总生存期,且3-4级高血压、蛋白尿等不良事件显著增加。

要点

  • 联合贝伐珠单抗延长PFS(HR 0.77),内分泌敏感患者获益更明显(HR 0.68)。
  • 联合治疗未改善总生存期(HR 0.96)。
  • 联合治疗显著增加3-4级高血压、蛋白尿等毒性。

核心结论

  • 内分泌治疗联合贝伐珠单抗可延长HR阳性转移性乳腺癌一线治疗的PFS,但未改善OS,且毒性显著增加。

研究设计与样本

  • 汇总LEA和CALGB 40503两项III期随机试验数据,共749例HR阳性转移性乳腺癌患者随机接受内分泌治疗或内分泌治疗联合贝伐珠单抗。

主要发现

  • 中位PFS为14.3个月(内分泌治疗)对比19个月(联合贝伐珠单抗),未调整HR 0.77(95%CI 0.66-0.91,p<0.01)。
  • 客观缓解率分别为40%和61%(p<0.01),临床获益率分别为64%和77%(p<0.01)。
  • 总生存期无差异(HR 0.96,95%CI 0.77-1.18,p=0.68)。
  • 内分泌敏感患者联合贝伐珠单抗PFS更优(HR 0.68,95%CI 0.53-0.89,p=0.004)。
  • 联合贝伐珠单抗组3-4级高血压(2.2% vs 20.1%)、蛋白尿(0% vs 9.3%)、心血管事件(0.5% vs 4.2%)和肝脏事件(0% vs 2.9%)显著增加(均p<0.01)。

关键数值与推荐

  • 联合贝伐珠单抗组3-4级高血压发生率为20.1%,蛋白尿为9.3%,心血管事件为4.2%,肝脏事件为2.9%。
  • 高血压和蛋白尿并非疗效预测因子(交互检验p=0.33)。

临床怎么用

  • 对于内分泌敏感的HR阳性转移性乳腺癌患者,可考虑内分泌治疗联合贝伐珠单抗以延长PFS,但需权衡显著增加的高血压、蛋白尿等毒性。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomised trials comparing the efficacy of standard endocrine therapy (ET) versus experimental ET + bevacizumab (Bev) in 1st line hormone receptor-positive patients with metastatic breast cancer have thus far shown conflicting results. PATIENTS AND METHODS: We pooled data from two similar phase III randomised trials of ET ± Bev (LEA and Cancer and Leukemia Group B 40503) to increase precision in estimating treatment effect. Primary end-point was progression-free survival (PFS). Secondary end-points were overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR) and safety. Exploratory analyses were performed within subgroups defined by patients with recurrent disease, de novo disease, prior endocrine sensitivity or resistance and reported grades III-IV hypertension and proteinuria. RESULTS: The pooled sample consisted of 749 patients randomised to ET or ET + Bev. Median PFS was 14.3 months for ET versus 19 months for ET + Bev (unadjusted hazard ratio [HR] 0.77; 95% confidence interval [CI] 0.66-0.91; p < 0.01). ORR and CBR with ET and ET + Bev were 40 versus 61% (p < 0.01) and 64 versus 77% (p < 0.01), respectively. There was no difference in OS (HR 0.96; 95% CI 0.77-1.18; p = 0.68). PFS was superior for ET + Bev for endocrine-sensitive patients (HR 0.68; 95% CI 0.53-0.89; p = 0.004). Grade III-IV hypertension (2.2 versus 20.1%), proteinuria (0 versus 9.3%), cardiovascular (0.5 versus 4.2%) and liver events (0 versus 2.9%) were significantly higher for ET + Bev (all p < 0.01). Hypertension and proteinuria were not predictors of efficacy (interaction test p = 0.33). CONCLUSION: The addition of Bev to ET increased PFS overall and in endocrine-sensitive patients but not OS at the expense of significant additional toxicity. TRIALS REGISTRATION: ClinicalTrial.Gov NCT00545077 and NCT00601900.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Martín M, Loibl S, Hyslop T, et al. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J Cancer. 2019. PMID: 31276981. doi:10.1016/j.ejca.2019.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。